| Literature DB >> 3136565 |
Abstract
Treatment of normal rats with certain monoclonal anti-CD4 antibodies, beginning on the day of grafting, prevents heart graft rejection across a full MHC-haplotype mismatch. Adequate doses of antibody MRC OX-35, which is very potent in vivo, led to the induction of authentic specific tolerance of the transplants. In the very stringent grafting test of transplantation of DA skin to high-responder LOU recipients, adjunctive therapy with cyclosporine, in addition to the anti-CD4 antibodies, is required to induce tolerance. Since tolerance persists indefinitely after a 30-day course of treatment and appears to involve T cell-mediated suppression, this form of treatment is of potential clinical interest.Entities:
Mesh:
Substances:
Year: 1988 PMID: 3136565 DOI: 10.1097/00007890-198808001-00024
Source DB: PubMed Journal: Transplantation ISSN: 0041-1337 Impact factor: 4.939